Semaglutide and Protein Intake: How Much and Why

At a glance

  • Protein target on the label / None; Wegovy says reduced-calorie diet plus more physical activity [1]
  • Ozempic diet instruction / Adjunct to diet and exercise; no weight-loss indication [2]
  • Nausea, Wegovy 2.4 mg / 44% vs 16% on placebo [1]
  • Diarrhea, vomiting, constipation / 30% vs 16%, 24% vs 6%, 24% vs 11% [1]
  • Decreased appetite, tablets / 6% on 7 mg, 9% on 14 mg vs 1% [3]
  • STEP 1 weight change / -14.9% vs -2.4% at 68 weeks [4]

What the labels say about diet

The Wegovy indication is written for use with a reduced-calorie diet and more physical activity, and that is the whole of the diet instruction in the indication [1]. Ozempic is an adjunct to diet and exercise for glycemic control, cardiovascular risk reduction and kidney outcomes in type 2 diabetes [2]. Neither indication names a protein target or a gram figure for any macronutrient [1][2]. Ozempic has no weight-loss indication; that indication belongs to Wegovy [2][1].

Appetite, gastric emptying and GI reactions

Semaglutide binds and activates the GLP-1 receptor, including receptors in brain areas that regulate appetite and calorie intake, and it delays gastric emptying [1].

In pooled placebo-controlled Wegovy trials of 2.4 mg weekly in adults with obesity or overweight, up to 68 weeks (2,116 on Wegovy, 1,261 on placebo), nausea occurred in 44% vs 16%, diarrhea in 30% vs 16%, vomiting in 24% vs 6%, constipation in 24% vs 11% and abdominal pain in 20% vs 10%. Any GI reaction was 73% vs 47%, and 6.8% vs 3.2% stopped treatment for an adverse reaction [1]. The Ozempic label says that most reports of nausea, vomiting and diarrhea occurred during dose escalation [2]. On the tablets, reduced appetite is itself listed as an adverse reaction, at 6% on 7 mg and 9% on 14 mg versus 1% on placebo [3].

What the weight-loss trials measured

STEP 1 enrolled 1,961 adults with a BMI of 30 or higher (27 or higher with a weight-related condition) and no diabetes, randomized 2:1 to semaglutide 2.4 mg weekly or placebo for 68 weeks with lifestyle intervention. Mean weight change was -14.9% versus -2.4%, and 86.4% versus 31.5% lost at least 5% [4]. Those figures are changes in total body weight.

Oral tablets and food timing

Ozempic injection has no food timing rule; it is given once weekly at any time of day, with or without meals [2]. For oral semaglutide tablets, the label specifies an empty stomach, up to 4 ounces of plain water, swallowing the tablet whole, and waiting at least 30 minutes before food, drinks or other oral medicines [1][3].

Frequently asked questions

Does semaglutide make it harder to eat enough protein?
The labels do not address protein intake, but gastrointestinal reactions are common on it. Nausea (44% vs 16%), diarrhea (30% vs 16%), vomiting (24% vs 6%) and constipation (24% vs 11%) were more common on Wegovy 2.4 mg than placebo, and the Ozempic label says most nausea, vomiting and diarrhea reports came during dose escalation [1][2].
What diet does the Wegovy label describe?
A reduced-calorie diet with more physical activity, stated in the indication itself [1].
Can I take oral semaglutide with a protein shake?
The tablet label specifies up to 4 ounces of plain water on an empty stomach, then waiting at least 30 minutes before food, drinks or other oral medicines [1][3]. The injection can be given with or without meals [2].
How much weight did people lose in the main trial?
In STEP 1, 1,961 adults without diabetes lost a mean of 14.9% of body weight on semaglutide 2.4 mg weekly over 68 weeks versus 2.4% on placebo [4].

References

  1. U.S. National Library of Medicine, DailyMed. Wegovy injection and Wegovy tablets (Novo Nordisk) prescribing information. Wegovy injection and Wegovy tablets (Novo Nordisk) label
  2. U.S. National Library of Medicine, DailyMed. Ozempic injection (Novo Nordisk) prescribing information. Ozempic injection (Novo Nordisk) label
  3. U.S. National Library of Medicine, DailyMed. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) prescribing information. Rybelsus and Ozempic tablets (Novo Nordisk) (oral semaglutide) label
  4. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Once-Weekly Semaglutide in Adults with Overweight or Obesity
Evidence overview for Semaglutide and Protein Intake: How Much and Why